ClinicalTrials.gg
CompletedNCT03137069Updated Sep 29, 2020Results posted

A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).

A Phase 2 interventional study of GDC-0853 and Placebo in Urticaria, sponsored by Genentech, Inc.. Completed at 27 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-09-29.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 47 studies in Urticaria with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Urticaria · United States.

Enrollment
10th of 37
134 · median 39
Started
2017
with 2 others
Phase 2
16 of 47
2 open now
Registered
30th of 47
by date
Lead sponsor
3 of 47
Genentech, Inc.

Among the 47 studies in Urticaria with a site in United States, this one is the 10th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2017, is one of 16 in phase 2, and was the 30th registered.

Urticaria

148 studies on the registry are indexed under Urticaria; 19 are open to participants now.

Browse Urticaria studies →

Open to participants now

4 of the 47 studies in Urticaria with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Urticaria studies recruiting now, 3 (25%) set no upper age limit and 6 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Urticaria with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of GDC-0853 compared with placebo in participants with Refractory Chronic Spontaneous Urticaria (CSU) already treated with anti-histamines. Participants have the option to enter the Open-Label Extension (OLE) study after completing the 8-week treatment period.

03

Conditions studied

  • Urticaria

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-75 years, inclusive
  • Diagnosis of chronic spontaneous urticaria (CSU) to H1 antihistamines at the time of randomization
  • Willing and able to complete an Urticaria Participant Daily eDiary for the duration of the study
  • No evidence of active or latent or inadequately treated infection with tuberculosis (TB)
  • Partcipants with a history of Bacille Calmette-Guérin (BCG) vaccination should be screened using the QuantiFERON-TB-Gold (QFT) test
  • Only for participants currently receiving proton-pump inhibitors (PPIs) or H2 receptor antagonists (H2RAs): Treatment must be at a stable dose during the 2-week screening period prior to randomization and with a plan to remain at a stable dose for the duration of the study
  • For women of : Agreement to remain abstinent (refrain from heterosexual intercourse) or use methods that result in a failure rate of \<1% per year during the treatment period and for at least 4 weeks after the last dose of study drug. Women must refrain from donating eggs during this same period.

Exclusion criteria

Exclusion Criteria:

  • Treatment with omalizumab or other monoclonal antibody therapies used to treat CSU within 4 months prior to screening or primary nonresponse to omalizumab
  • Use of a non-biologic drug or participation in an investigational study with a non-biologic drug within 30 days prior to study drug administration on Day 1 (or within 5 half-lives of the investigational product, whichever is greater)
  • Use of a biologic investigational therapy or participation in an investigational study involving biologic therapy within 90 days or 5 half-lives, whichever is greater, prior to study drug administration on Day 1
  • Previous treatment with GDC-0853 or other Bruton's tyrosine kinase (BTK) inhibitors
  • Participants whose urticaria is solely due to physical urticaria
  • Other diseases with symptoms of urticaria or angioedema, including urticarial vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary or acquired angioedema, lymphoma, or leukemia
  • Atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, or other skin disease associated with itch such as psoriasis
  • Routine doses of the following medications within 30 days prior to screening: systemic or cutaneous (topical) (prescription or over the counter), hydroxychloroquine, methotrexate, cyclosporine, or cyclophosphamide
  • Prior utilization of intravenous (IV) steroids for treatment of laryngeal angioedema
  • Intravenous immunoglobulin G (IV IG) or plasmapheresis within 30 days prior to screening
  • History of anaphylactic shock without clearly identifiable avoidable antigen
  • to GDC-0853 or any component of the formulation
  • Major surgery within 8 weeks prior to screening or surgery planned prior to end of study (12 weeks after randomization)
  • Require any prohibited concomitant medications
  • History of within 6 weeks prior to randomization or requirement to receive these vaccinations at any time during study drug treatment
  • Evidence of cardiac, neurologic, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, or gastrointestinal (GI) disease that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participant participation
  • Current treatment with astemizole, terfenadine, and/or ebastine
  • Uncontrolled disease states, such as asthma, psoriasis, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
134 participants (actual)

Study arms

  • Placebo comparator
    Cohort 1: Placebo

    Participants received matching placebo twice daily from Day 1 to 56.

    Drug: Placebo

  • Experimental
    Cohort 1: GDC-0853 200mg BID

    Participants received GDC-0853 200mg twice daily from Day 1 to 56.

    Drug: GDC-0853

  • Placebo comparator
    Cohort 2: Placebo

    Participants received matching placebo up to twice daily from Day 1 to 56.

    Drug: Placebo

  • Experimental
    Cohort 2: GDC-0853 50mg QD

    Participants received GDC-0853 50mg once daily from Day 1 to 56.

    Drug: GDC-0853

  • Experimental
    Cohort 2: GDC-0853 150mg QD

    Participants received GDC-0853 150mg once daily from Day 1 to 56.

    Drug: GDC-0853

  • Experimental
    Cohort 2: GDC-0853 200mg BID

    Participants received GDC-0853 200mg twice daily from Day 1 to 56.

    Drug: GDC-0853

Interventions

  • GDC-0853 will be administered orally at dosages of 50, 150 and 200mg to participants, as per the dosing schedules described above.

  • DrugPlacebo

    Matching Placebo will be administered orally, as per the dosing schedules described above.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Day 57

    The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates worse disease. A negative change score (Day 57 score minus Baseline score) indicates improvement.

    Time frame: Baseline and Day 57

Secondary outcomes

  1. Percentage of Participants Who Are Well-Controlled (UAS7 ≤ 6)

    The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates worse disease. Participants with UAS7 score ≤6 are considered well controlled.

    Time frame: Day 57

  2. Change From Baseline in the UAS7 at Day 29

    The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates worse disease. A negative change score (Day 29 score minus Baseline score) indicates improvement.

    Time frame: Baseline and Day 29

  3. Percentage of Participants With Adverse Events (AEs)

    An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as Adverse Events.

    Time frame: Baseline up until 4 weeks after the last dose of study drug (up to 2 years, 5 months).

  4. Plasma Concentrations of Fenebrutinib (GDC-0853) at Specified Timepoints

    Plasma Concentration Data for fenebrutinib (GDC-0853) will be tabulated and summarised by visits. Descriptive summary statistics for Arithmetic Mean and Standard Deviation will be presented. Please note that the Placebo Cohorts were not evaluated for this Outcome Measure.

    Time frame: Days 1, 8 and 57.

07

Results

Posted Sep 29, 2020
Limitations and caveats
Recruitment was stopped after an interim analysis of Cohort 2 based on pre-specified internal criteria.

Participant flow

The study was conducted at 21 centers in 3 countries.

Participant flow — Overall Study
MilestoneCohort 1: PlaceboCohort 1: GDC-0853 200mg BIDCohort 2: PlaceboCohort 2: GDC-0853 50mg QDCohort 2: GDC-0853 150mg QDCohort 2: GDC-0853 200mg BID
Started132823232423
Completed122220172221
Not completed163622
Withdrew: Withdrawal by subject122200
Withdrew: Adverse event031101
Withdrew: Protocol violation010111
Withdrew: Physician decision000100
Withdrew: Study terminated by sponsor000010
Withdrew: Data entry error000100

Outcome measures

PrimaryChange From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Day 57

The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates worse disease. A negative change score (Day 57 score minus Baseline score) indicates improvement.

Time frame:
Baseline and Day 57
Reported as:
Mean · Score on a Scale
Change From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Day 57
Score on a ScaleCohort 1: PlaceboCohort 1: GDC-0853 200mg BIDCohort 2: PlaceboCohort 2: GDC-0853 50mg QDCohort 2: GDC-0853 150mg QDCohort 2: GDC-0853 200mg BID
Change From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Day 57-19.16 ± 13.49-24.05 ± 9.74-11.25 ± 10.81-15.69 ± 14.25-17.05 ± 10.19-21.80 ± 14.80
Statistical analysis
  • Cohort 1: Placebo vs Cohort 1: GDC-0853 200mg BID · Mixed Models Analysis · p = 0.0559 · Least squares mean difference: -7.02 · 90% CI -13.01 to -1.03Covariates included were region, treatment group, visit, and visit by treatment group interaction
  • Cohort 2: Placebo vs Cohort 2: GDC-0853 50mg QD · Mixed Models Analysis · p = 0.8892 · Least squares mean difference: -0.51 · 90% CI -6.60 to 5.58Covariates included were region, treatment group, visit, and visit by treatment group interaction
  • Cohort 2: Placebo vs Cohort 2: GDC-0853 150mg QD · Mixed Models Analysis · p = 0.0717 · Least squares mean difference: -6.43 · 90% CI -12.29 to -0.57Covariates included were region, treatment group, visit, and visit by treatment group interaction
  • Cohort 2: Placebo vs Cohort 2: GDC-0853 200mg BID · Mixed Models Analysis · p = 0.0097 · Least squares mean difference: -9.53 · 90% CI -15.50 to -3.55Covariates included were region, treatment group, visit, and visit by treatment group interaction
SecondaryPercentage of Participants Who Are Well-Controlled (UAS7 ≤ 6)

The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates worse disease. Participants with UAS7 score ≤6 are considered well controlled.

Time frame:
Day 57
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Are Well-Controlled (UAS7 ≤ 6)
Percentage of ParticipantsCohort 1: PlaceboCohort 1: GDC-0853 200mg BIDCohort 2: PlaceboCohort 2: GDC-0853 50mg QDCohort 2: GDC-0853 150mg QDCohort 2: GDC-0853 200mg BID
Percentage of Participants Who Are Well-Controlled (UAS7 ≤ 6)30.857.121.734.845.856.5
Statistical analysis
  • Cohort 1: Placebo vs Cohort 1: GDC-0853 200mg BID · Cochran-Mantel-Haenszel · p = 0.1087Stratified by region
  • Cohort 2: Placebo vs Cohort 2: GDC-0853 50mg QD · Cochran-Mantel-Haenszel · p = 0.3418Stratified by region
  • Cohort 2: Placebo vs Cohort 2: GDC-0853 150mg QD · Cochran-Mantel-Haenszel · p = 0.0459Stratified by region
  • Cohort 2: Placebo vs Cohort 2: GDC-0853 200mg BID · Cochran-Mantel-Haenszel · p = 0.0190Stratified by region
SecondaryChange From Baseline in the UAS7 at Day 29

The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates worse disease. A negative change score (Day 29 score minus Baseline score) indicates improvement.

Time frame:
Baseline and Day 29
Reported as:
Mean · Score on a Scale
Change From Baseline in the UAS7 at Day 29
Score on a ScaleCohort 1: PlaceboCohort 1: GDC-0853 200mg BIDCohort 2: PlaceboCohort 2: GDC-0853 50mg QDCohort 2: GDC-0853 150mg QDCohort 2: GDC-0853 200mg BID
Change From Baseline in the UAS7 at Day 29-9.69 ± 10.70-22.15 ± 10.33-9.05 ± 9.82-16.97 ± 14.31-13.75 ± 12.93-21.69 ± 16.22
Statistical analysis
  • Cohort 1: Placebo vs Cohort 1: GDC-0853 200mg BID · Mixed Models Analysis · p = 0.0010 · Least squares mean difference: -12.88 · 90% CI -18.94 to -6.82Covariates included were region, treatment group, visit, and visit by treatment group interaction
  • Cohort 2: Placebo vs Cohort 2: GDC-0853 50mg QD · Mixed Models Analysis · p = 0.4565 · Least squares mean difference: -2.83 · 90% CI -9.11 to 3.46Covariates included were region, treatment group, visit, and visit by treatment group interaction
  • Cohort 2: Placebo vs Cohort 2: GDC-0853 150mg QD · Mixed Models Analysis · p = 0.1711 · Least squares mean difference: -5.03 · 90% CI -11.10 to 1.03Covariates included were region, treatment group, visit, and visit by treatment group interaction
  • Cohort 2: Placebo vs Cohort 2: GDC-0853 200mg BID · Mixed Models Analysis · p = 0.0050 · Least squares mean difference: -10.76 · 90% CI -16.97 to -4.56Covariates included were region, treatment group, visit, and visit by treatment group interaction
SecondaryPercentage of Participants With Adverse Events (AEs)

An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as Adverse Events.

Time frame:
Baseline up until 4 weeks after the last dose of study drug (up to 2 years, 5 months).
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events (AEs)
Percentage of ParticipantsCohort 1: PlaceboCohort 1: GDC-0853 200mg BIDCohort 2: PlaceboCohort 2: GDC-0853 50mg QDCohort 2: GDC-0853 150mg QDCohort 2: GDC-0853 200mg BID
Percentage of Participants With Adverse Events (AEs)61.571.454.560.966.758.3
SecondaryPlasma Concentrations of Fenebrutinib (GDC-0853) at Specified Timepoints

Plasma Concentration Data for fenebrutinib (GDC-0853) will be tabulated and summarised by visits. Descriptive summary statistics for Arithmetic Mean and Standard Deviation will be presented. Please note that the Placebo Cohorts were not evaluated for this Outcome Measure.

Time frame:
Days 1, 8 and 57.
Reported as:
Mean · ng/mL
Plasma Concentrations of Fenebrutinib (GDC-0853) at Specified Timepoints
ng/mLCohort 1: GDC-0853 200mg BIDCohort 2: GDC-0853 50mg QDCohort 2: GDC-0853 150mg QDCohort 2: GDC-0853 200mg BID
Day 1NA ± NANA ± NANA ± NANA ± NA
Day 8378 ± 38938.5 ± 36.9178 ± 237424 ± 385
Day 57283 ± 31519.6 ± 26.324.7 ± 17.7219 ± 293

Adverse events

Collected over Baseline up until 4 weeks after the last dose of study drug (up to 2 years, 5 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Placebo0/13 (0%)0/13 (0%)8/13 (61.5%)
Cohort 1: GDC-0853 200mg BID0/28 (0%)3/28 (10.7%)16/28 (57.1%)
Cohort 2: Placebo0/22 (0%)0/22 (0%)7/22 (31.8%)
Cohort 2: GDC-0853 50mg QD0/23 (0%)0/23 (0%)7/23 (30.4%)
Cohort 2: GDC-0853 150mg QD0/24 (0%)0/24 (0%)13/24 (54.2%)
Cohort 2: GDC-0853 200mg BID0/24 (0%)0/24 (0%)12/24 (50%)
Most frequent serious events
Most frequent serious events
EventCohort 1: PlaceboCohort 1: GDC-0853 200mg BIDCohort 2: PlaceboCohort 2: GDC-0853 50mg QDCohort 2: GDC-0853 150mg QDCohort 2: GDC-0853 200mg BID
ABDOMINAL PAIN UPPERGastrointestinal disorders0/131/280/220/230/240/24
PERIORBITAL CELLULITISInfections and infestations0/131/280/220/230/240/24
HEPATIC ENZYME INCREASEDInvestigations0/131/280/220/230/240/24
Most frequent other events
Showing 10 of 22
Most frequent other events
EventCohort 1: PlaceboCohort 1: GDC-0853 200mg BIDCohort 2: PlaceboCohort 2: GDC-0853 50mg QDCohort 2: GDC-0853 150mg QDCohort 2: GDC-0853 200mg BID
NASOPHARYNGITISInfections and infestations3/137/281/223/233/243/24
HEADACHENervous system disorders3/134/282/220/231/243/24
URTICARIASkin and subcutaneous tissue disorders0/135/282/223/234/245/24
ALANINE AMINOTRANSFERASE INCREASEDInvestigations0/132/280/220/231/243/24
DIARRHOEAGastrointestinal disorders0/131/282/220/231/240/24
FATIGUEGeneral disorders0/131/282/220/231/240/24
NAUSEAGastrointestinal disorders0/132/280/221/232/242/24
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations0/131/281/220/230/242/24
URINARY TRACT INFECTIONInfections and infestations0/130/280/221/232/241/24
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations0/132/280/220/231/242/24

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1: PlaceboCohort 1: GDC-0853 200mg BIDCohort 2: PlaceboCohort 2: GDC-0853 50mg QDCohort 2: GDC-0853 150mg QDCohort 2: GDC-0853 200mg BIDTotal
Mean43.6 ± 11.041.3 ± 15.940.2 ± 14.745.0 ± 13.143.3 ± 16.744.3 ± 13.042.8 ± 14.4
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: PlaceboCohort 1: GDC-0853 200mg BIDCohort 2: PlaceboCohort 2: GDC-0853 50mg QDCohort 2: GDC-0853 150mg QDCohort 2: GDC-0853 200mg BIDTotal
Female112217182016104
Male26654730
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: PlaceboCohort 1: GDC-0853 200mg BIDCohort 2: PlaceboCohort 2: GDC-0853 50mg QDCohort 2: GDC-0853 150mg QDCohort 2: GDC-0853 200mg BIDTotal
Hispanic or Latino01525215
Not Hispanic or Latino132716211920116
Not Stated0010012
Unknown0010001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: PlaceboCohort 1: GDC-0853 200mg BIDCohort 2: PlaceboCohort 2: GDC-0853 50mg QDCohort 2: GDC-0853 150mg QDCohort 2: GDC-0853 200mg BIDTotal
Asian03431415
Black or African American1111026
White102418192316110
Multiple2000013
08

Study locations

27 sites
  • Clinical Research Center of Alabama, LLC
    Birmingham, Alabama 35209, United States
  • Allergy & Asthma Immunology Associates
    Scottsdale, Arizona 85251, United States
  • Kern Allergy Med Clinic, Inc.
    Bakersfield, California 93301, United States
  • Southern California Research Center
    Mission Viejo, California 92691, United States
  • Allergy & Asthma Consultants
    Redwood City, California 94063, United States
  • Integrated Research Group Inc
    Riverside, California 92506, United States
  • Integrated Research of Inland
    Upland, California 91786, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Vital Prospects Clinical Research Institute PC - CRN
    Tulsa, Oklahoma 74136, United States
  • Asthma, Nasal Disease, and Allergy Research Center of New England
    East Providence, Rhode Island 02914, United States
  • Center for Clinical Studies
    Cypress, Texas 77433, United States
  • Timber Lane Allergy and Asthma Research, LLC
    Burlington, Vermont 05403, United States
  • University of British Columbia
    Vancouver, British Columbia V6T 1Z4, Canada
  • Private Practice - Dr. Jason Ohayon
    Hamilton, Ontario L8S 1G5, Canada
  • Lynde Institute for Dermatology
    Markham, Ontario L3P 1X2, Canada
  • Cheema Research
    Mississauga, Ontario L5A 3V4, Canada
  • Yang Medicine
    Ottawa, Ontario K1G 6C6, Canada
  • Gordon Sussman Clinical Research
    Toronto, Ontario M4V 1R2, Canada
  • Private Practice - Dr. Isabelle Delorme
    Drummondville, Quebec J2B 5L4, Canada
  • Centre de Recherche Applique En Allergie de Quebec
    Quebec City, Quebec G1V 4M6, Canada
  • Licca Clinical Research Institute
    Augsburg, 86179, Germany
  • Charite Mitte; Klinik fur Dermatologie
    Berlin, 10117, Germany
  • Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Augenheilkunde
    Dresden, 01307, Germany
  • Hautarztpraxis Mahlow
    Mahlow, 15831, Germany
  • Universitätsmedizin Johannes Gutenberg Universität
    Mainz, 55131, Germany
  • Klinik für Haut- und Geschlechtskrankheiten, Universitätsklinikum Münster
    Münster, 48419, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Sep 2019, 28 months.

Results were first posted in Sep 2020, 1 year after primary completion.

Of 13 phase 2 interventional studies under Urticaria, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's 28 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2017
First posted
May 2, 2017
StartActual
May 26, 2017
Primary completionActual
Sep 27, 2019
CompletionActual
Oct 25, 2019
Results first posted
Sep 29, 2020
Last update
Sep 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03137069
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
May 2, 2017
Start date
May 26, 2017
Primary completion
Sep 27, 2019
Completion
Oct 25, 2019
Results posted
Sep 29, 2020
Last update
Sep 29, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenebrutinib

Start the discussion